DFDaniel Plimmer Furkert

Daniel Plimmer Furkert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel Plimmer Furkert has a total of 143 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Membrane lipid composition: an important but neglected aspect of membrane protein simulation

    by Beatrix L. Goggin, Daniel P. Furkert, Jane R. Allison

    Membranes are heterogeneous 2D mixtures of integral membrane proteins and lipids.

  • Synthesis of Triazenes via Enolate Addition to Azides

    by Siyuan Li, Daniel Plimmer Furkert

    The triazene moiety has found diverse applications as synthetic intermediates and in bioactive molecules. Here, the synthesis of triazenes by the addition of lithium amide enolates to azides is reported. One-pot electrophilic trapping afforded a range of novel triazenes in good yields. These studies further build understanding of azide–enolate reactions, and the convenient method reported is expected to expand the accessible chemical space of available triazenes.

  • Total Synthesis of (−)‐Cordycicadin D and 3,4‐trans‐Cordycicadins A and B: Entry to the 3,4‐trans‐Fused Cordycicadin Framework

    by Liam R. Hunt, Phillip S. Grant, Grace K. Shimokura, Daniel P. Furkert, Margaret A. Brimble

    Cordycicadins A−D are four C20 polyketides, all containing a γ‐lactone fused to a 10‐membered lactone. The proposed biosynthetic pathway for the cordycicadins anticipates the formation of two more natural products which are unknown. We report the total synthesis of (–)‐cordycicadin D and the two anticipated natural products 3,4‐trans‐cordycicadins A and B. The targets were convergently assembled, in a biomimetic fashion, via an efficient ketene trapping‐intramolecular Michael addition sequence that delivered the requisite 3,4‐trans‐fused framework with high diastereoselectivity, enabled by the synthesis of complex dioxenones that serve as in situ ketene precursors. Recognition of the embedded polyketide symmetry enabled the use of a divergent‐convergent synthetic strategy, based on the use of two products from an early‐stage enzymatic resolution. The synthetic routes afforded (–)‐cordycicadin D in 14 steps and 3,4‐trans‐cordycicadins A and B in 13 steps (longest linear sequence). This work confirms the structure of (−)‐cordycicadin D and the observed instability of the anticipated natural product 3,4‐trans‐cordycicadin B during purification may explain why it is yet to be isolated.

  • Total Synthesis of (−)‐Cordycicadin D and 3,4‐trans‐Cordycicadins A and B: Entry to the 3,4‐trans‐Fused Cordycicadin Framework

    by Liam R. Hunt, Phillip S. Grant, Grace K. Shimokura, Daniel P. Furkert, Margaret A. Brimble

    Cordycicadins A−D are four C20 polyketides, all containing a γ‐lactone fused to a 10‐membered lactone. The proposed biosynthetic pathway for the cordycicadins anticipates the formation of two more natural products which are unknown. We report the total synthesis of (–)‐cordycicadin D and the two anticipated natural products 3,4‐trans‐cordycicadins A and B. The targets were convergently assembled, in a biomimetic fashion, via an efficient ketene trapping‐intramolecular Michael addition sequence that delivered the requisite 3,4‐trans‐fused framework with high diastereoselectivity, enabled by the synthesis of complex dioxenones that serve as in situ ketene precursors. Recognition of the embedded polyketide symmetry enabled the use of a divergent‐convergent synthetic strategy, based on the use of two products from an early‐stage enzymatic resolution. The synthetic routes afforded (–)‐cordycicadin D in 14 steps and 3,4‐trans‐cordycicadins A and B in 13 steps (longest linear sequence). This work confirms the structure of (−)‐cordycicadin D and the observed instability of the anticipated natural product 3,4‐trans‐cordycicadin B during purification may explain why it is yet to be isolated.


  • Open Access

    Total Synthesis of (–)-Cordycicadin D and 3,4-trans-Cordycicadins A and B: Entry to the 3,4-trans-Fused Cordycicadin Framework

    by Liam Hunt, Phillip Grant, Grace Shimokura, Daniel Furkert, Margaret Brimble

    Cordycicadins A–D are four C20 polyketides, all containing a gamma-lactone fused to a 10-membered lactone. The proposed biosynthetic pathway for the cordycicadins anticipates the formation of two more natural products which are unknown. We report the total synthesis of (–)-cordycicadin D and the two anticipated natural products 3,4-trans-cordycicadins A and B. The targets were convergently assembled, in a biomimetic fashion, via an efficient ketene trapping-intramolecular Michael addition sequence that delivered the requisite 3,4-trans-fused framework with high diastereoselectivity, enabled by the synthesis of complex dioxenones that serve as in situ ketene precursors. Recognition of the embedded polyketide symmetry enabled the use of a divergent-convergent synthetic stratergy, based on the use of two products from an early-stage enzymatic resolution. The synthetic routes afforded (–)-cordycicadin D in 14 steps and 3,4-trans-cordycicadins A and B in 13 steps (longest linear sequence). This work confirms the structure of (–)-cordycicadin D, and notes that observed instability of the anticipated natural product 3,4-trans-cordycicadin B during purification may explain why it is yet to be isolated.

  • Identification of Chemical Scaffolds That Inhibit the Mycobacterium tuberculosis Respiratory Complex Succinate Dehydrogenase

    by Cara Adolph, Kiel Hards, Zoe C. Williams, Chen-Yi Cheung, Laura M. Keighley, William J. Jowsey, Matson Kyte, Daniel Ken Inaoka, Kiyoshi Kita, Jared S. Mackenzie, et al.

    Drug-resistant Mycobacterium tuberculosis is a significant cause of infectious disease morbidity and mortality for which new antimicrobials are urgently needed. Inhibitors of mycobacterial respiratory energy metabolism have emerged as promising next-generation antimicrobials, but a number of targets remain unexplored. Succinate dehydrogenase (SDH), a focal point in mycobacterial central carbon metabolism and respiratory energy production, is required for growth and survival in M. tuberculosis under a number of conditions, highlighting the potential of inhibitors targeting mycobacterial SDH enzymes. To advance SDH as a novel drug target in M. tuberculosis, we utilized a combination of biochemical screening and in-silico deep learning technologies to identify multiple chemical scaffolds capable of inhibiting mycobacterial SDH activity. Antimicrobial susceptibility assays show that lead inhibitors are bacteriostatic agents with activity against wild-type and drug-resistant strains of M. tuberculosis. Mode of action studies on lead compounds demonstrate that the specific inhibition of SDH activity dysregulates mycobacterial metabolism and respiration and results in the secretion of intracellular succinate. Interaction assays demonstrate that the chemical inhibition of SDH activity potentiates the activity of other bioenergetic inhibitors and prevents the emergence of resistance to a variety of drugs. Overall, this study shows that SDH inhibitors are promising next-generation antimicrobials against M. tuberculosis.


  • Synthesis of the bicyclic butenolide core of pallamolide A: a biomimetic approach

    by Grace J. Drummond, Phillip S. Grant, Alisha M. Geurts, Daniel P. Furkert, Margaret A. Brimble

    Pallamolide A is a 7,8-seco-labdane terpenoid possessing a unique bicyclo[2.2.2]octane core and a spiro-butenolide moiety. A biomimetic synthesis of the bicyclic butenolide core over 10 steps is reported, featuring an unexpected autoxidation ring opening, and a vinylogous Mukaiyama aldol reaction which was spontaneously followed by an unusual intramolecular vinylogous aldol reaction to assemble the spiro-butenolide moiety and bicyclic core of pallamolide A.


  • Open Access

    Essential Dynamics of CB 1 Receptor-Agonist Complexes: Implications for Signalling Bias

    by Daniel M. J. Fellner, Michelle Glass, Daniel P. Furkert

    The CB 1 cannabinoid receptor is implicated in a broad range of physiological processes and disease states, however CB 1 -targeting drugs in clinical use remain based on tetrahydrocannabinol (THC). Ligands that exhibit functional selectivity for different intracellular signalling pathways are currently an area of rapid development, and hold significant potential as therapeutic agents. Improved understanding of the exact molecular mechanisms underpinning biased activation of intracellular effector proteins for CB 1 is necessary to enable drug development of biased CB 1 ligands into candidates for treatment of human disease. Using molecular dynamics, this study shows that CB 1 conformations resulting from activation by the orthosteric ligands CP55940, Δ9-THC or 5F-MDMB-PICA exhibit differences in the dynamic organisation of key residues and receptor substructures involved in coupling to G proteins and β-arrestins, that leads to selective activation of downstream signalling pathways. The identification of conformationally distinct CB 1 -agonist complexes that demonstrate different functional profiles provides an important step in unravelling the molecular determinants for biased signalling, and lays a platform for future rational design of novel therapeutic leads.


  • Open Access

    Determination of the Cannabinoid CB1 Receptor’s Positive Allosteric Modulator Binding Site through Mutagenesis Studies

    by Hayley M. Green, Daniel M. J. Fellner, David B. Finlay, Daniel P. Furkert, Michelle Glass

    Positive allosteric modulators (PAMs) of the cannabinoid CB1 receptor (CB1) offer potential therapeutic advantages in the treatment of neuropathic pain and addiction by avoiding the adverse effects associated with orthosteric CB1 activation. Here, molecular modeling and mutagenesis were used to identify residues central to PAM activity at CB1. Six putative allosteric binding sites were identified in silico, including novel sites previously associated with cholesterol binding, and key residues within each site were mutated to alanine. The recently determined ZCZ011 binding site was found to be essential for allosteric agonism, as GAT228, GAT229 and ZCZ011 all increased wild-type G protein dissociation in the absence of an orthosteric ligand; activity that was abolished in mutants F191A3.27 and I169A2.56. PAM activity was demonstrated for ZCZ011 in the presence of the orthosteric ligand CP55940, which was only abolished in I169A2.56. In contrast, the PAM activity of GAT229 was reduced for mutants R220A3.56, L404A8.50, F191A3.27 and I169A2.56. This indicates that allosteric modulation may represent the net effect of binding at multiple sites, and that allosteric agonism is likely to be mediated via the ZCZ011 site. This study underlines the need for detailed understanding of ligand receptor interactions in the search for pure CB1 allosteric modulators.


  • Synthesis and α-Functionalisation of Cyclic Imines

    by Margaret A. Brimble, Ze Kuang, Xiao-Bo Ding, Daniel Plimmer Furkert

    α-Functionalisation of cyclic imines is explored. The cyclic imine substrates are synthesised from their respective halonitrile precursors using a nucleophilic addition/cyclisation sequence. Selective monohalogenation of the cyclic imines yields α-haloimines, which serve as a platform to obtain various α-hydroxyimine derivatives. In addition, an unusual tautomerisation and oxidation sequence is observed in the attempted preparation of α-hydroxyimines.